The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of simmitinib, a novel tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R.
 
Sheng Yang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Mingjun Zhang
No Relationships to Disclose
 
Yongzhong Wu
No Relationships to Disclose
 
Yongsheng Li
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Xin Tian
No Relationships to Disclose
 
Suxia Luo
Consulting or Advisory Role - KYM Biosciences
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Linlin Wang
No Relationships to Disclose
 
Jiancheng Li
No Relationships to Disclose
 
Da Jiang
No Relationships to Disclose
 
Mingxia Wang
No Relationships to Disclose
 
Yunchao Huang
No Relationships to Disclose
 
Huaqiu Shi
No Relationships to Disclose
 
Haiyu Yang
No Relationships to Disclose
 
Xiaowen Liu
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Wei Ji
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Weiqing Pu
Employment - CSPC ZhongQi Pharmaceutical Technology
 
Yuankai Shi
No Relationships to Disclose